Forte Biosciences, Inc. (FBRX)
76.94
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
76.94
0.00 (0.00%)
After-Hours: 20:00
Forte Biosciences Enterprise Value : 1.377B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.377B |
| August 20, 2026 | 1.376B |
| August 19, 2026 | 1.377B |
| August 18, 2026 | 1.376B |
| August 17, 2026 | 1.376B |
| August 14, 2026 | 1.375B |
| August 13, 2026 | 1.376B |
| August 12, 2026 | 1.374B |
| August 11, 2026 | 1.376B |
| August 10, 2026 | 1.375B |
| August 07, 2026 | 1.374B |
| August 06, 2026 | 1.375B |
| August 05, 2026 | 1.371B |
| August 04, 2026 | 1.370B |
| August 03, 2026 | 1.371B |
| July 31, 2026 | 1.370B |
| July 30, 2026 | 1.378B |
| July 29, 2026 | 1.369B |
| July 28, 2026 | 1.372B |
| July 27, 2026 | 1.368B |
| July 24, 2026 | 923.57M |
| July 23, 2026 | 1.024B |
| July 22, 2026 | 961.46M |
| July 21, 2026 | 840.61M |
| July 20, 2026 | 774.25M |
| Date | Value |
|---|---|
| July 17, 2026 | 802.31M |
| July 16, 2026 | 723.04M |
| July 15, 2026 | 705.84M |
| July 14, 2026 | 686.38M |
| July 13, 2026 | 705.22M |
| July 10, 2026 | 701.13M |
| July 09, 2026 | 553.24M |
| July 08, 2026 | 223.07M |
| July 07, 2026 | 257.27M |
| July 06, 2026 | 219.59M |
| July 02, 2026 | 230.03M |
| July 01, 2026 | 238.22M |
| June 30, 2026 | 236.79M |
| June 29, 2026 | 238.35M |
| June 26, 2026 | 234.32M |
| June 25, 2026 | 202.05M |
| June 24, 2026 | 199.68M |
| June 23, 2026 | 194.26M |
| June 22, 2026 | 196.06M |
| June 18, 2026 | 190.08M |
| June 17, 2026 | 186.47M |
| June 16, 2026 | 180.35M |
| June 15, 2026 | 192.87M |
| June 12, 2026 | 186.05M |
| June 11, 2026 | 183.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| argenx SE | 64.28B |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
| Savara, Inc. | 1.006B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.33M |
| Total Expenses (Quarterly) | 23.33M |
| EPS Diluted (Quarterly) | -0.9808 |
| Earnings Yield | -6.67% |
| Normalized Earnings Yield | -6.667 |